National Cancer Institute (NCI) is part of the NIH, one of 11 agencies that are part of the U.S. Department of Health and Human Services. NCI coordinates the U.S. National Cancer Program, which conducts and supports research, training, health information dissemination and other activities related to the cause, prevention, diagnosis, and treatment of cancer; cancer survivorship; and the continuing care of cancer patients and their families.
NCI, Center for Global Health (CGH) supports the NCI mission by advancing global cancer research and coordinating NCI engagement in global cancer control. CGH also represents NCI in international research partnerships, playing a key role in coordinating multinational research efforts for global benefit. Core values for CGH are impact, equity, and collaboration. These values inform CGH efforts to lead innovative, impactful programs with partners within and outside NCI. CGH goals are focused on research, research training, dissemination, and partnership, primarily in low- and middle-income countries (LMICs). Areas of scientific focus include new technologies, implementation science, cancer health disparities, clinical trials, and cancer etiology.
Visit  www.cancer.gov  for further information.

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it’s personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 120 countries and listed on Nasdaq Stockholm.

 Visit www.elekta.com for more information.

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world.
Novartis Sub-Saharan Africa (SSA) was established in November 2019 when the region embarked on a transformational journey to operate as a single Novartis unit under one leadership, integrating the strengths and capabilities of three business units, namely Pharma, Oncology, and Sandoz. Novartis SSA comprises 46 countries and is headquartered in Nairobi, Kenya.

 Visit www.novartis.com for more information.

Takeda is a global biopharmaceutical leader committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. Takeda believes access to healthcare and medicines should be universal. However, across the world, many people lack access to the services and treatment they need. We are working to achieve greater health equity for all patients by addressing health disparities and inequities that disproportionately impact underserved communities, including access to clinical trials.  Together with strategic partners across multiple sectors, we are committed to helping strengthen healthcare systems in a sustainable way, at every stage of the patient journey – from awareness and diagnosis, to treatment, and ongoing patient support.

 Visit www.takeda.com for more information.

Varian is the world’s leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Visit www.varian.com for more information.

The American Cancer Society is on a mission to free the world from cancer. We work with partners in Sub-Saharan Africa to reduce cancer incidence, and to support cancer patients by accelerating diagnoses and improving access to high quality, affordable treatment and supportive care.

Visit www.cancer.org for further information.

Advancing research and discovery is our foundation, built on an 80-year legacy of innovation.At Beckman Coulter, we are dedicated to advancing and optimizing the laboratory. For more than 80 years, we have been a trusted partner for laboratory professionals, helping to advance scientific research and patient care. We have a vital role: our focus on innovation, reliability and efficiency has led us to become the partner of choice for clinical, research and industrial customers around the globe.
Visit www.beckmancoulter.com for further information.

The mission of the Bristol Myers Squibb Foundation is to promote health equity and improve the health outcomes of populations disproportionately affected by serious diseases by strengthening healthcare worker capacity, integrating medical care and community-based supportive services and mobilizing communities in the fight against disease.
The Foundation’s Global Cancer Disparities Initiative seeks to strengthen cancer care systems and community supportive services for heavily burdened populations facing a range of pediatric and adult cancers in sub–Saharan Africa, Brazil, China and the US.
Visit www.bms.com/foundation for further information.

Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation’s (NYSE: DHR) Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company’s solutions deliver a better way for institutions of any size to perform sophisticated molecular diagnostic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer.

Visit www.cepheid.com for further information.

International Gynecologic Cancer Society
Uniting the globe in the fight against gynecologic cancers.
The mission of the International Gynecologic Cancer Society is to enhance the care of women with gynecologic cancer worldwide through education and training and public awareness. The society works to achieve its mission through strategic collaborations with regional and international organizations, hosting and supporting scientific meetings, promoting research and publications, providing mentorship and training opportunities and patient advocacy programming.
The concept of global health equity is embedded in the IGCS mission and is reflected in the breadth of its membership and the design and implementation of its programs. With over 3,000 members from low-, middle-, and high-income countries around the globe, IGCS has purposefully developed an inclusive membership framework that encourages interaction and growth across diverse social, political, and health care systems. Through this framework, IGCS connects members with specific needs to those with corresponding resources and programs; forms partnerships; educates, trains, and mentors clinicians, survivors-patients, and caregivers.
Visit www.igcs.org for further information.

Nuclear technology plays a key role in the diagnosis and treatment of cancer. The IAEA has six decades of experience in helping countries respond to the growing cancer burden. From training staff in the safe, secure and effective use of radiotherapy to procuring equipment for diagnosis and treatment, providing quality assurance services.

The IAEA’s Programme of Action for Cancer Therapy also provides assistance through imPACT Reviews, resource mobilization, and by supporting the development of strategic documents such as Comprehensive National Cancer Control Plans and bankable documents for fundraising. In addition, the IAEA Human Health Programme provides a holistic approach to the prevention, diagnosis and treatment of non-communicable diseases, covering four main support areas: nutrition; diagnosis and follow-up; radiation oncology and radiotherapy; and quality assurance. Our Human Health Campus is an online information resource for health professionals working in nuclear medicine, radiation oncology, medical physics, and nutrition, providing insight into the different aspects of modern clinical practice.

Visit www.iaea.org for further information.

City Cancer Challenge Foundation (C/Can) supports cities around the world as they work to improve access to equitable, quality cancer care. C/Can leads a city-based partnership initiative that aims to improve access to quality cancer care in cities around the world by transforming the way stakeholders from the public and private sectors collectively design, plan, and implement cancer solutions.
The approach is built on the core principle that cities can drive impact at a national level by crafting data-driven solutions with the support of a network of global, regional, and local partners that reflect an understanding of the unique local context. C/Can was launched by the Union for International Cancer Control (UICC) at the 2017 World Economic Forum Annual Meeting in Davos. It was established as a standalone Swiss foundation in January 2019.

Visit www.citycancerchallenge.org for further information.

Visit www.crdfglobal.org for further information.

The Center for Health Equity and Community Engagement Research at Mayo Clinic partners with communities to allow everyone to achieve the highest possible level of well-being and health. We work with internal and external stakeholders to develop the strategic direction and initiatives aimed at creating innovative solutions to health disparities throughout the course of life to advance the ideal of health equity.

Visit www.mayo.edu for further information.

The Global Cancer Program at the UCSF Helen Diller Family Comprehensive Cancer Center aims to reduce the global cancer burden through innovative research, education, and collaboration.  Our objectives are three-fold: (1) To perform innovative research that addresses the disparate burden of cancer in LMICs; (2) To provide education, research training, and mentorship for early career investigators in LMICs and at UCSF focused on global cancer research; and (3) To foster collaborations between UCSF and healthcare systems in LMICs to sustainably impact the global cancer burden.

Visit globalcancer.ucsf.edu for further information.

University of North Carolina Lineberger Comprehensive Cancer Center
One of the leading cancer centers in the nation, the University of North Carolina Lineberger Comprehensive Cancer Center is located in Chapel Hill, North Carolina. As one of only 52 National Cancer Institute-designated Comprehensive Cancer Centers, UNC Lineberger was recently rated as exceptional – the highest category – by the National Cancer Institute. The center brings together some of the most exceptional physicians and scientists in the country to investigate and improve the prevention, early detection and treatment of cancer. With research that spans the spectrum from the laboratory to the bedside to the community, UNC Lineberger faculty work to understand the causes of cancer at the genetic and environmental levels, to conduct groundbreaking laboratory research, and to translate findings into pioneering and innovative clinical trials that benefit the citizens across North Carolina and around the globe.

Visit www.unclineberger.org for further information.